These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 31639132)

  • 1. Sarcopenia as a prognostic factor for survival in patients with locally advanced gastroesophageal adenocarcinoma.
    Koch C; Reitz C; Schreckenbach T; Eichler K; Filmann N; Al-Batran SE; Götze T; Zeuzem S; Bechstein WO; Kraus T; Bojunga J; Düx M; Trojan J; Blumenstein I
    PLoS One; 2019; 14(10):e0223613. PubMed ID: 31639132
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Perioperative chemotherapy vs. neoadjuvant chemoradiation in gastroesophageal junction adenocarcinoma : A population-based evaluation of the Munich Cancer Registry.
    Münch S; Habermehl D; Agha A; Belka C; Combs SE; Eckel R; Friess H; Gerbes A; Nüssler NC; Schepp W; Schmid RM; Schmitt W; Schubert-Fritschle G; Weber B; Werner J; Engel J
    Strahlenther Onkol; 2018 Feb; 194(2):125-135. PubMed ID: 29071366
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is advanced esophageal adenocarcinoma a distinct entity from intestinal subtype gastric cancer? Data from the AGAMENON-SEOM Registry.
    Alvarez-Manceñido F; Jimenez-Fonseca P; Carmona-Bayonas A; Arrazubi V; Hernandez R; Cano JM; Custodio A; Pericay Pijaume C; Aguado G; Martínez Lago N; Sánchez Cánovas M; Cacho Lavin D; Visa L; Martinez-Torron A; Arias-Martinez A; López F; Limón ML; Vidal Tocino R; Fernández Montes A; Alsina M; Pimentel P; Reguera P; Martín Carnicero A; Ramchandani A; Granja M; Azkarate A; Martín Richard M; Serra O; Hernández Pérez C; Hurtado A; Gil-Negrete A; Sauri T; Morales Del Burgo P; Gallego J
    Gastric Cancer; 2021 Jul; 24(4):926-936. PubMed ID: 33651195
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RACE-trial: neoadjuvant radiochemotherapy versus chemotherapy for patients with locally advanced, potentially resectable adenocarcinoma of the gastroesophageal junction - a randomized phase III joint study of the AIO, ARO and DGAV.
    Lorenzen S; Biederstädt A; Ronellenfitsch U; Reißfelder C; Mönig S; Wenz F; Pauligk C; Walker M; Al-Batran SE; Haller B; Hofheinz RD
    BMC Cancer; 2020 Sep; 20(1):886. PubMed ID: 32933498
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preoperative docetaxel/cisplatin/5-fluorouracil chemotherapy in patients with locally advanced gastro-esophageal adenocarcinoma.
    Bayraktar UD; Bayraktar S; Hosein P; Chen E; Koniaris LG; Rocha-Lima CM; Montero AJ
    Med Oncol; 2012 Sep; 29(3):1707-10. PubMed ID: 22033912
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The RENAISSANCE (AIO-FLOT5) trial: effect of chemotherapy alone vs. chemotherapy followed by surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction - a phase III trial of the German AIO/CAO-V/CAOGI.
    Al-Batran SE; Goetze TO; Mueller DW; Vogel A; Winkler M; Lorenzen S; Novotny A; Pauligk C; Homann N; Jungbluth T; Reissfelder C; Caca K; Retter S; Horndasch E; Gumpp J; Bolling C; Fuchs KH; Blau W; Padberg W; Pohl M; Wunsch A; Michl P; Mannes F; Schwarzbach M; Schmalenberg H; Hohaus M; Scholz C; Benckert C; Knorrenschild JR; Kanngießer V; Zander T; Alakus H; Hofheinz RD; Roedel C; Shah MA; Sasako M; Lorenz D; Izbicki J; Bechstein WO; Lang H; Moenig SP
    BMC Cancer; 2017 Dec; 17(1):893. PubMed ID: 29282088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of Locally Advanced Gastroesophageal Cancer: Still a Multidisciplinary Global Challenge?
    Al-Batran SE; Lorenzen S
    Hematol Oncol Clin North Am; 2017 Jun; 31(3):441-452. PubMed ID: 28501086
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sarcopenia: Prevalence, and Impact on Operative and Oncologic Outcomes in the Multimodal Management of Locally Advanced Esophageal Cancer.
    Elliott JA; Doyle SL; Murphy CF; King S; Guinan EM; Beddy P; Ravi N; Reynolds JV
    Ann Surg; 2017 Nov; 266(5):822-830. PubMed ID: 28796017
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sarcopenia is associated with toxicity in patients undergoing neo-adjuvant chemotherapy for oesophago-gastric cancer.
    Tan BH; Brammer K; Randhawa N; Welch NT; Parsons SL; James EJ; Catton JA
    Eur J Surg Oncol; 2015 Mar; 41(3):333-8. PubMed ID: 25498359
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of repeat staging laparoscopy in locoregionally advanced gastric or gastroesophageal cancer after neoadjuvant therapy.
    Cardona K; Zhou Q; Gönen M; Shah MA; Strong VE; Brennan MF; Coit DG
    Ann Surg Oncol; 2013 Feb; 20(2):548-54. PubMed ID: 22941159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gastroesophageal Junction Adenocarcinoma: Is There an Optimal Management?
    Lin D; Khan U; Goetze TO; Reizine N; Goodman KA; Shah MA; Catenacci DV; Al-Batran SE; Posey JA
    Am Soc Clin Oncol Educ Book; 2019 Jan; 39():e88-e95. PubMed ID: 31099690
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group.
    Wagner AD; Grabsch HI; Mauer M; Marreaud S; Caballero C; Thuss-Patience P; Mueller L; Elme A; Moehler MH; Martens U; Kang YK; Rha SY; Cats A; Tokunaga M; Lordick F
    BMC Cancer; 2019 May; 19(1):494. PubMed ID: 31126258
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Evaluation of the value of 7th editions of UICC-AJCC esophageal and gastric cancer TNM staging systems for prognostic prediction of adenocarcinoma of esophagogastric junction (Siewert type II)].
    Shi GD; Luo ZL; Fu MY; Tian D; Zhang L; Zhang KP
    Zhonghua Zhong Liu Za Zhi; 2014 Dec; 36(12):916-21. PubMed ID: 25623766
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes of Neoadjuvant Chemoradiation in Patients with Gastro-esophageal Junction Adenocarcinoma: a Retrospective Cohort Study in Iran.
    Farhan F; Ghalehtaki R; Mahdavi-Seresht S; Meysamie A; Yamrali M; Farazmand B; Mohammadi N; Saraee E; Mir MR; Mir A; Lashkari M; Salarvand S; Esmati E; Samiei F
    J Gastrointest Cancer; 2019 Dec; 50(4):907-912. PubMed ID: 30402826
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A retrospective comparative exploratory study on two methylentetrahydrofolate reductase (MTHFR) polymorphisms in esophagogastric cancer: the A1298C MTHFR polymorphism is an independent prognostic factor only in neoadjuvantly treated gastric cancer patients.
    Blank S; Rachakonda S; Keller G; Weichert W; Lordick F; Langer R; Springfeld C; Bruckner T; Becker K; Kumar R; Ott K
    BMC Cancer; 2014 Feb; 14():58. PubMed ID: 24490800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor downstaging after neoadjuvant chemotherapy determines survival after surgery for gastric adenocarcinoma.
    Levenson G; Voron T; Paye F; Balladur P; Debove C; Chafai N; De Dios AG; Lefevre JH; Parc Y
    Surgery; 2021 Dec; 170(6):1711-1717. PubMed ID: 34561115
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Carbohydrate antigen 19-9 is a useful prognostic marker in esophagogastric junction adenocarcinoma.
    Tokunaga R; Imamura Y; Nakamura K; Uchihara T; Ishimoto T; Nakagawa S; Iwatsuki M; Baba Y; Sakamoto Y; Miyamoto Y; Yoshida N; Oyama S; Shono T; Naoe H; Saeki H; Oki E; Watanabe M; Sasaki Y; Maehara Y; Baba H
    Cancer Med; 2015 Nov; 4(11):1659-66. PubMed ID: 26310928
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Perioperative chemo(radio)therapy versus primary surgery for resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus.
    Ronellenfitsch U; Schwarzbach M; Hofheinz R; Kienle P; Kieser M; Slanger TE; Jensen K;
    Cochrane Database Syst Rev; 2013 May; (5):CD008107. PubMed ID: 23728671
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survival in Patients With Esophageal Adenocarcinoma Undergoing Trimodality Therapy Is Independent of Regional Lymph Node Location.
    Sepesi B; Schmidt HE; Lada M; Correa AM; Walsh GL; Mehran RJ; Rice DC; Roth JA; Vaporciyan AA; Ajani JA; Watson TJ; Swisher SG; Low DE; Hofstetter WL
    Ann Thorac Surg; 2016 Mar; 101(3):1075-80; Discussion 1080-1. PubMed ID: 26680311
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors predicting survival in patients with proximal gastric carcinoma involving the esophagus.
    Zhang YF; Shi J; Yu HP; Feng AN; Fan XS; Lauwers GY; Mashimo H; Gold JS; Chen G; Huang Q
    World J Gastroenterol; 2012 Jul; 18(27):3602-9. PubMed ID: 22826627
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.